Despite being one of the least potent GSIs in preclinical studies (155), DAPT has proven to be efficacious as single agent in treating NSCLC with altered NOTCH signaling pathway members (74), in inducing apoptosis and autophagy, preferentially in cells expressing EGFR wild type or without EGFR expression (132), by inducing cell cycle arrest in G1 and G2/M phases (98), and reducing the ALDH+ stem cell population (156). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.